IMMUNE EPITOPE DATABASE AND ANALYSIS PROGRAM
ID: 75N93024R00017Type: Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFNATIONAL INSTITUTES OF HEALTHNATIONAL INSTITUTES OF HEALTH NIAIDBETHESDA, MD, 20892, USA

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

PSC

HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (AN12)

Original Source

https://sam.gov/opp/e7908d74caf340fba8b451ba6e9395e2/view
Timeline
    Description

    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is soliciting proposals for the Immune Epitope Database and Analysis Program, aimed at providing researchers with critical data on antibody and T-cell epitopes related to various health conditions. The initiative seeks to continue support for this program, which is essential for advancing biomedical research in infectious diseases, allergies, and autoimmunity. Proposals must be submitted by November 19, 2024, with a base performance period from October 15, 2025, to October 14, 2026, and potential extensions in subsequent years. Interested parties should contact Brandon de White at whitebra@niaid.nih.gov or Tom Bahrami at bahramit@niaid.nih.gov for further details.

    Files
    Title
    Posted
    75N93024R00017.pdf
    The National Institutes of Health (NIH) issued a Request for Proposal (RFP) aimed at continuing support for the Immune Epitope Database and Analysis Program. The RFP outlines requirements for proposals to be submitted by 11/19/2024. This initiative provides researchers with a resource to explore data on antibody and T-cell epitopes related to infectious diseases, allergies, and autoimmunity. The document specifies the submission and evaluation process, including the necessity for offers to be registered in the System for Award Management (SAM). Key details include the base period of performance from 10/15/2025 to 10/14/2026, with options for extensions in subsequent years. Reporting requirements specify electronic submissions conforming to Section 508 standards, and continuous updates on technical progress are mandated. Special contract provisions address the protection of human subjects, NIH reproducibility policies, and acknowledgement of federal funding. The solicitation emphasizes compliance with various regulations including financial conflict of interest reporting and information security standards, highlighting the government’s commitment to transparency and accountability in its funded research activities. Overall, this RFP reflects NIH's efforts to bolster biomedical research infrastructure while safeguarding sensitive information.
    Lifecycle
    Title
    Type
    IMMUNE EPITOPE DATABASE AND ANALYSIS PROGRAM
    Currently viewing
    Solicitation
    Similar Opportunities
    A--Request for Proposals - Phase I Clinical Trials
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Phase I clinical trials aimed at developing small molecule and biologics therapeutics, as outlined in RFP No. 75N95024R00086. The selected contractor will be responsible for comprehensive services including protocol development, trial management, and reporting to regulatory agencies, with a focus on safety, tolerability, and pharmacokinetics of the investigational therapeutics. This initiative is crucial for advancing therapeutic development in the field of neurology, ensuring compliance with FDA and ICH GCP standards throughout the trial process. Proposals are due by October 3, 2024, with a contract performance period from April 1, 2025, to March 31, 2035, and a maximum contract value of $233,227,446. Interested parties can contact Evan C. Feely at evan.feely@nih.gov or +1 301 827 5301 for further information.
    A Solicitation of the National Institutes of Health (NIH) and The Centers for Disease Control and Prevention (CDC) for Small Business Innovation Research (SBIR) Contract Proposals
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC) seek proposals from small businesses for innovative research projects under the Small Business Innovation Research (SBIR) program. The upcoming solicitation, PHS-2025-1, will open on August 2, 2024, with a closing date of October 18, 2024, and aims to foster healthcare technological innovation and commercialization. Research topics span cancer research, aging, and various health concerns. Offerors must demonstrate the technical and commercial viability of their proposals. This solicitation invites applications for Phase I, Fast Track, and Direct to Phase II projects, with evaluations based on scientific merit, commercial potential, and performance quality. Successful small businesses could receive funding for their research initiatives, contributing to NIH and CDC mission objectives.
    NIAID Virology Quality Assurance
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID), is seeking qualified small business sources for the NIAID Virology Quality Assurance (VQA) program. The primary objective is to establish a comprehensive quality assessment program for virologic assays related to HIV and other viral pathogens, ensuring the validity and reliability of laboratory data across approximately 110 laboratories globally. This initiative is crucial for maintaining the scientific integrity of ongoing and future studies concerning HIV diagnosis, treatment, and emerging viral pathogens. Interested parties must submit their capability statements by September 26, 2024, to Shawnice Williams at shawnice.williams@nih.gov, with a focus on demonstrating relevant experience and qualifications.
    DRAFT Decentralized Engineering of Cells Informed by Dynamic Evidence (DECIDE) Exploration Topic
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H), is soliciting proposals for the Decentralized Engineering of Cells Informed by Dynamic Evidence (DECIDE) exploration topic. This initiative aims to enhance access to curative cell therapies for pediatric patients with rare genetic diseases by developing novel quality assurance mechanisms at Academic Medical Centers (AMCs) over a structured 24-month program. The program will focus on identifying manufacturing variability, improving batch quality through signature identification methodologies, and creating statistical tools to guide production decisions, ultimately streamlining the development of small batch autologous cell therapies. Proposals are due by October 22, 2024, and interested parties should direct inquiries to the designated email address provided in the solicitation.
    A--BPCA Pediatric Trials Network
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is soliciting proposals for an Indefinite Quantity Contract to establish and manage the Best Pharmaceuticals for Children Act (BPCA) Pediatric Trials Network. This initiative aims to create a robust infrastructure for conducting pediatric clinical trials, emphasizing compliance with federal regulations and ethical standards in research practices. The contract, which has a performance period from May 19, 2025, to May 18, 2033, offers a minimum compensation of $2,500 and a maximum potential value of $149 million, contingent on successful performance. Proposals are due by November 4, 2024, and interested parties can contact Elizabeth J. Osinski at eo43m@nih.gov or 240-550-5028 for further information.
    Surface Plasmon Resonance (SPR) Instrument- Brand Name or Equal
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), is seeking quotes for a Surface Plasmon Resonance (SPR) Instrument, either brand name or equal, to support its Vaccine Research Center's structural biology efforts. The procurement aims to acquire a high-throughput SPR instrument that meets specific technical requirements, including dimensions, weight, temperature ranges, and data collection capabilities, to facilitate biophysical and structural analysis of macromolecules. This equipment is critical for advancing research in infectious diseases and vaccine development. Interested vendors must submit their quotes by 4:30 PM EST on September 19, 2024, to Hershea Vance at hershea.vance@nih.gov, and ensure compliance with all specified requirements and clauses outlined in the solicitation documents.
    Automated Liquid Handling Systems– Brand Name or Equal
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH), is seeking quotes for the procurement of two automated liquid handling systems, either brand name or equal, to support the Vaccine Production Program (VPP) at the National Institute of Allergy and Infectious Diseases (NIAID). These systems are critical for high-throughput, microscale protein purification and product characterization, which are essential for developing vaccines against various pathogens, including HIV and SARS-COV-2. Interested vendors must submit their quotes by 12:00 PM EST on September 23, 2024, to Daveta H. Brown at daveta.brown@nih.gov, ensuring compliance with all specified requirements and regulations outlined in the solicitation documents.
    Alto Instrument with Nicosystem Pro - Brand Name or Equal
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the National Institutes of Health (NIH) through the National Institute of Allergy and Infectious Diseases (NIAID), is seeking quotations for the procurement of two biolayer interferometer instruments, either brand name or equal, to support monoclonal antibody and vaccine development projects at its Vaccine Research Center. The instruments must meet specific technical requirements, including high-throughput capabilities, integration with existing liquid handling systems, and user-friendly analysis software, to facilitate the efficient quantification of proteins and other biological samples. Interested vendors must submit their quotes by September 17, 2024, with delivery expected within 30 days post-award, and are required to be registered in the System for Award Management (SAM). For further inquiries, vendors can contact Hershea Vance at hershea.vance@nih.gov or Linda Smith at linda.smith2@nih.gov.
    Good Manufacturing Practice (GMP)-manufactured Monoclonal Antibody
    Active
    Health And Human Services, Department Of
    The National Institutes of Health (NIH), specifically the National Institute of Allergy and Infectious Diseases (NIAID), intends to award a sole source contract for the procurement of Good Manufacturing Practice (GMP)-manufactured Monoclonal Antibody UB-421, with a requirement of 100 liters. This procurement is critical for an ongoing clinical trial aimed at treating patients with multidrug-resistant HIV-1 infection, utilizing UB-421, which is exclusively manufactured by United BioPharma, Inc., the sole patent holder and provider of the necessary cell line for production. Interested parties who believe they can meet the specifications must submit a capability statement to the primary contact, Hershea Vance, by 3:00 PM EST on September 20, 2024, as the contract is expected to be awarded within 19 days of this notice, with a performance period from September 23, 2024, to September 24, 2025.
    Chemistry, Manufacturing and Controls and Related Services for Development of Drug Substances
    Active
    Health And Human Services, Department Of
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is seeking proposals for Chemistry, Manufacturing, and Controls (CMC) services related to the development of drug substances. The primary objective is to ensure the Division of Preclinical Innovation (DPI) receives drug substances of adequate quality and quantity to support preclinical and Investigational New Drug (IND)-enabling studies, adhering to current Good Manufacturing Practice (cGMP) standards. This procurement is crucial for advancing therapeutics from preclinical stages to market readiness, emphasizing a multidisciplinary approach and compliance with regulatory requirements throughout the drug development pipeline. The Request for Proposals (RFP) is expected to be released on or about October 4, 2024, with contract awards anticipated in the second quarter of FY2025. Interested parties may contact Samson Shifaraw at samson.shifaraw@nih.gov for further information.